Journal: EJNMMI research

Article Title: Novel GAL7-targeted fluorescent molecular imaging probe for high-grade squamous intraepithelial lesion and cervical cancer screening.

doi: 10.1186/s13550-025-01218-6

Figure Lengend Snippet: Fig. 1 Schematic of the experimental procedure of targeted fluorescent probe GAL7-FITC for the targeted imaging and diagnosis of HSIL/cervical cancer. (a) Preclinical animal experiments. (b) Clinical imaging procedure of cone biopsy

Article Snippet: Firstly, anti-Gal7 antibody (0.2 mg/mL, 150 μL, Proteintech) or IgG2a (9.7 mg/mL, 120 μL, Bioxcell) was dissolved in 1 mL of dimethyl sulfoxide (DMSO, Solarbio).

Techniques: Imaging, Biomarker Discovery

Journal: EJNMMI research

Article Title: Novel GAL7-targeted fluorescent molecular imaging probe for high-grade squamous intraepithelial lesion and cervical cancer screening.

doi: 10.1186/s13550-025-01218-6

Figure Lengend Snippet: Fig. 2 Expression of GAL7. (a) Statistical analysis of GAL7 expression in CESC tumor and normal tissues obtained from the GEPIA database. Log2(TPM + 1) was used for the log-scale. (b) Western blotting analysis of GAL7 protein expression in various cell lines (H8, SiHa, HeLa, and C33-A). (c) & (d) Representa tive GAL7 IHC and H&E histology obtained from human and mouse xenograft cervical cancer tissues. (e) IHC scores of GAL7 expression in IHC samples. Scale bar of overview, 200 μm. Scale bar of cancer and normal, 50 μm. * P < 0.05, ** P < 0.01, **** P < 0.0001. CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; HSIL, high-grade squamous cell carcinoma; SCC, squamous intraepithelial lesion; AC, adenocarcinoma

Article Snippet: Firstly, anti-Gal7 antibody (0.2 mg/mL, 150 μL, Proteintech) or IgG2a (9.7 mg/mL, 120 μL, Bioxcell) was dissolved in 1 mL of dimethyl sulfoxide (DMSO, Solarbio).

Techniques: Expressing, Western Blot

Journal: EJNMMI research

Article Title: Novel GAL7-targeted fluorescent molecular imaging probe for high-grade squamous intraepithelial lesion and cervical cancer screening.

doi: 10.1186/s13550-025-01218-6

Figure Lengend Snippet: Fig. 3 Characterization and uptake of GAL7-FITC. (a) Absorption and fluorescence emission spectra of of GAL7-FITC and IgG2a-FITC. (b) FACS of H8, SiHa, HeLa, and C-33 A cells stained with GAL7-FITC. (c) FACS MFI of different cell lines. (d) Cell viabiliaty of different cell lines (SiHa, HeLa, C-33, and H8) stained with different concentrations of GAL7-FITC. * P < 0.05, ** P < 0.01

Article Snippet: Firstly, anti-Gal7 antibody (0.2 mg/mL, 150 μL, Proteintech) or IgG2a (9.7 mg/mL, 120 μL, Bioxcell) was dissolved in 1 mL of dimethyl sulfoxide (DMSO, Solarbio).

Techniques: Fluorescence, Staining

Journal: EJNMMI research

Article Title: Novel GAL7-targeted fluorescent molecular imaging probe for high-grade squamous intraepithelial lesion and cervical cancer screening.

doi: 10.1186/s13550-025-01218-6

Figure Lengend Snippet: Fig. 4 Fluorescence microscopic imaging and subcellular localization of GAL7-FITC in different cell lines (H8, SiHa, C-33 A and HeLa). Lysosomes were stained with LAMP2 (pink). Mitochondria were stained with TOMM20 (red). Nuclei were stained with DAPI (blue). Scale bar, 50 μm

Article Snippet: Firstly, anti-Gal7 antibody (0.2 mg/mL, 150 μL, Proteintech) or IgG2a (9.7 mg/mL, 120 μL, Bioxcell) was dissolved in 1 mL of dimethyl sulfoxide (DMSO, Solarbio).

Techniques: Fluorescence, Imaging, Staining

Journal: EJNMMI research

Article Title: Novel GAL7-targeted fluorescent molecular imaging probe for high-grade squamous intraepithelial lesion and cervical cancer screening.

doi: 10.1186/s13550-025-01218-6

Figure Lengend Snippet: Fig. 5 Fluorescence molecular imaging (FMI) of cervical cancer and HSIL tissue stained with GAL7-FITC. (a) FMI of ex vivo xenograft tumors (SiHa, HeLa, and C33-A), HSIL and in-situ squamous cervical carcinoma of mice. (b) Fluorescence intensity of GAL7-FITC and IgG2a-FITC. (c) Analysis of MFI of cervical cancer and HSIL tissue stained with GAL7-FITC. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Firstly, anti-Gal7 antibody (0.2 mg/mL, 150 μL, Proteintech) or IgG2a (9.7 mg/mL, 120 μL, Bioxcell) was dissolved in 1 mL of dimethyl sulfoxide (DMSO, Solarbio).

Techniques: Fluorescence, Imaging, Staining, Ex Vivo, In Situ

Journal: EJNMMI research

Article Title: Novel GAL7-targeted fluorescent molecular imaging probe for high-grade squamous intraepithelial lesion and cervical cancer screening.

doi: 10.1186/s13550-025-01218-6

Figure Lengend Snippet: Fig. 6 Specific binding of GAL7-FITC in HSIL biospecimens of mice and human patients. (a) Ex vivo CLE of tumor xenografts and HSIL of mice stained with GAL7-FITC. (b) CLE MFI analysis of tumor and HSIL. (c) Fluorescence microscopy scans of in-situ cervical SiHa squamous carcinoma stained with GAL7-FITC. (d) Fluorescence imaging (FI) of GAL7-FITC staining, H&E histology and GAL7 IHC staining of fresh HSIL biospecimens from a patient. Red lines indicate the area of cervical lesions. MFI: mean fluorescence intensity

Article Snippet: Firstly, anti-Gal7 antibody (0.2 mg/mL, 150 μL, Proteintech) or IgG2a (9.7 mg/mL, 120 μL, Bioxcell) was dissolved in 1 mL of dimethyl sulfoxide (DMSO, Solarbio).

Techniques: Binding Assay, Ex Vivo, Staining, Fluorescence, Microscopy, In Situ, Imaging, Immunohistochemistry